Seeking Alpha

Alnylam Pharmaceuticals (ALNY +5.2%) trades up after reporting encouraging pre-clinical data for...

Alnylam Pharmaceuticals (ALNY +5.2%) trades up after reporting encouraging pre-clinical data for its RNAi therapeutic program to treat of hemophilia and other bleeding disorders. The drug candidate produced up to a four-fold increase in thrombin - a protein that plays a role in blood coagulation - in testing with non-human primates. The company says it eventually plans to have five different medications in clinical development by the end of 2015.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs